













Regular chromogranin A monitoring facilitated the early 
detection of a gastrointestinal neuroendocrine tumour 
in a patient with type 1 diabetes 
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Neuroendocrine tumours (NET) are rare, slow-growing 
malignancies in most cases [1]. Chromogranin A (CgA) 
is used routinely as a biochemical marker to diagnose 
and monitor NETs. Furthermore, the connection be-
tween CgA and diabetes was shown [1, 2].
Serum CgA level of type 1 diabetes (T1DM) patients 
were screened, and the patients with CgA levels above 
or close to the upper level of normal range (19.4–98.1 
ng/mL) were followed up regularly [3]. A 58-year-old 
male T1DM patient’s CgA level was measured at 82.2 
ng/mL in 2006. The chromogranin A level was slowly 
rising, and the CgA level was already above the normal 
range in 2015 (Fig. 1). The increase of CgA was above 
the expected average annual increase of CgA [3]. The 
patient was negative for common CgA-elevating condi-
tions, such as autoimmune gastritis or enterochromaf-
fin-like cell hyperplasia.
In late 2019 the patient’s serum CgA level was higher 
than before, and he started to complain about mild diar-
rhoea and epigastric discomfort. Due to the high CgA 
level and uncertain symptoms, further investigations 
were performed: stool microbiology test (Escherichia 
coli, Clostridium difficile, Salmonella spp., Shigella spp., 
Yersinia enterocolitica, Campylobacter spp. and Caliciviri-
dae), gastroscopy, and colonoscopy were all negative; 
a computed tomography (CT) scan of the abdomen 
showed a hypervascularised area in the mesentery, 
caudally from the duodenum. On a previous CT scan 
dated from 2015, which was also performed due to the 
elevation in CgA level, the deviations above were not 
visible. Fine-needle aspiration of the area indicated 
on the CT scan confirmed a CgA- and synaptophy-
sin-positive grade I NET with low Ki-67 proliferation 
rate. Somatostatin receptor scintigraphy was positive 
for the tumour. Tumour markers, except CgA and 5-hy-
droxyindoleacetic acid, were within the normal range.
Surgical removal of the tumour and preoperative 
somatostatin analogue treatment was recommended 
by the Neuroendocrine Oncology Team, Semmelweis 
University. The primary tumour (1.5 × 1 cm) was 
resected from the ileum, approximately 50–70 cm 
away from the ileocecal valve. A 10 × 6 × 5 cm and 
a 7 × 5 × 4 cm lymph node conglomerate were also 
removed from the mesenteric root. Histological find-
ings strengthened the fine-needle aspiration results: 
tumour was a grade I, pT4N1M0 neuroendocrine lesion 
with immunohistologically confirmed CgA positivity, 
and Ki-67 positivity was less than 1%. Eight of the 22 
local lymph nodes were positive for metastasis. Based 
on the evaluation of the oncology team, the tumour 
had favourable histological prognostic parameters, and 
there was no sign of distant metastasis; therefore, close 
monitoring of the patient in every three months using 
CgA and 5-hydroxyindoleacetic acid measurements 
was considered sufficient for follow-up. One month 
after tumour removal, serum CgA returned almost to 
normal range (103 ng/mL, Fig. 1).
Serum CgA level is a useful marker to monitor the 
progression of both premalignant lesions and NETs 
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[1, 3, 4]. The causal relationship between the high and 
increasing levels of serum CgA and the presence of 
enterochromaffin-like cell hyperplasia, autoimmune 
gastritis, and NETs in patients with T1DM is highly 
probable [3, 4]. The removal of a gastrointestinal NET 
from this patient drastically decreased the serum CgA 
level supporting the described causal relationship. 
This case has clearly proven the usefulness of CgA as 
a marker to detect and follow-up NETs in patients with 
T1DM. During approximately 15 years of our observa-
tion this was the third, but best “CgA-documented” 
NET discovered from ~200 T1DM patients in our 
outpatient clinic. NETs have a higher incidence rate 
in T1DM than in the general population [5]; therefore, 
the routine measurement of CgA in T1DM (annually 
or every two years, for example) facilitates the early 
detection of gastrointestinal NETs. Even a moderate 
increase in the level of serum CgA may draw the clini-
cians’ attention, and further examinations by imaging 
techniques can be initiated, as well as early interven-
tion. We propose that serum CgA in patients with 
T1DM serves as a useful biomarker for early detection 
of gastrointestinal NETs.
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Figure 1. Changes of serum chromogranin A (CgA) levels of the patient between 2006 and 2020. Solid line shows the observed CgA 
levels, dot-dashed line with the grey range represents the CgA changes predicted with a random intercept mixed effect model [3]. Dotted 
line is the upper level of normal (ULN) of CgA (98.1 ng/mL), and the dashed line at the bottom shows glycated haemoglobin (HbA1c) 
levels during the ~14-year period
